These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30718600)

  • 1. Chronic kidney disease induces left ventricular overexpression of the pro-hypertrophic microRNA-212.
    Sárközy M; Gáspár R; Zvara Á; Siska A; Kővári B; Szűcs G; Márványkövi F; Kovács MG; Diószegi P; Bodai L; Zsindely N; Pipicz M; Gömöri K; Kiss K; Bencsik P; Cserni G; Puskás LG; Földesi I; Thum T; Bátkai S; Csont T
    Sci Rep; 2019 Feb; 9(1):1302. PubMed ID: 30718600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Heart Irradiation Induces Cardiac Overexpression of the Pro-hypertrophic miR-212.
    Sárközy M; Gáspár R; Zvara Á; Kiscsatári L; Varga Z; Kővári B; Kovács MG; Szűcs G; Fábián G; Diószegi P; Cserni G; Puskás LG; Thum T; Kahán Z; Csont T; Bátkai S
    Front Oncol; 2019; 9():598. PubMed ID: 31380269
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.
    Di Marco GS; Reuter S; Kentrup D; Grabner A; Amaral AP; Fobker M; Stypmann J; Pavenstädt H; Wolf M; Faul C; Brand M
    Nephrol Dial Transplant; 2014 Nov; 29(11):2028-35. PubMed ID: 24875663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adiponectin Upregulates MiR-133a in Cardiac Hypertrophy through AMPK Activation and Reduced ERK1/2 Phosphorylation.
    Li Y; Cai X; Guan Y; Wang L; Wang S; Li Y; Fu Y; Gao X; Su G
    PLoS One; 2016; 11(2):e0148482. PubMed ID: 26845040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-122 promotes cardiomyocyte hypertrophy via targeting FoxO3.
    Song G; Zhu L; Ruan Z; Wang R; Shen Y
    Biochem Biophys Res Commun; 2019 Nov; 519(4):682-688. PubMed ID: 31543343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ischemic preconditioning protects the heart against ischemia-reperfusion injury in chronic kidney disease in both males and females.
    Sárközy M; Márványkövi FM; Szűcs G; Kovács ZZA; Szabó MR; Gáspár R; Siska A; Kővári B; Cserni G; Földesi I; Csont T
    Biol Sex Differ; 2021 Sep; 12(1):49. PubMed ID: 34488888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypericin Alleviates Chronic Kidney Disease-induced Left Ventricular Hypertrophy by Regulation of FGF23-FGFR4 Signaling Pathway.
    Liu M; Cheng L; Ye Q; Liu H; Shu C; Gao H; Liu X; Zhang X; Chen G
    J Cardiovasc Pharmacol; 2024 Jun; 83(6):588-601. PubMed ID: 38547517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis.
    Gao XM; Wong G; Wang B; Kiriazis H; Moore XL; Su YD; Dart A; Du XJ
    J Hypertens; 2006 Aug; 24(8):1663-70. PubMed ID: 16877971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maxacalcitol (22-Oxacalcitriol (OCT)) Retards Progression of Left Ventricular Hypertrophy with Renal Dysfunction Through Inhibition of Calcineurin-NFAT Activity.
    Inoue K; Matsui I; Hamano T; Okuda K; Tsukamoto Y; Matsumoto A; Shimada K; Yasuda S; Katsuma Y; Takabatake Y; Tanaka M; Tanaka N; Mano T; Minamino T; Sakata Y; Isaka Y
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):381-397. PubMed ID: 33206298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts.
    Curcio A; Torella D; Iaconetti C; Pasceri E; Sabatino J; Sorrentino S; Giampà S; Micieli M; Polimeni A; Henning BJ; Leone A; Catalucci D; Ellison GM; Condorelli G; Indolfi C
    PLoS One; 2013; 8(7):e70158. PubMed ID: 23922949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-30 regulates left ventricular hypertrophy in chronic kidney disease.
    Bao J; Lu Y; She Q; Dou W; Tang R; Xu X; Zhang M; Zhu L; Zhou Q; Li H; Zhou G; Yang Z; Shi S; Liu Z; Zheng C
    JCI Insight; 2021 May; 6(10):. PubMed ID: 33848263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal denervation decreases susceptibility of the heart to ventricular fibrillation in a canine model of chronic kidney disease.
    Tang X; Shi L; Cui X; Yu Y; Qi T; Chen C; Tang X
    Exp Physiol; 2017 Nov; 102(11):1414-1423. PubMed ID: 28833735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
    Leifheit-Nestler M; Grabner A; Hermann L; Richter B; Schmitz K; Fischer DC; Yanucil C; Faul C; Haffner D
    Nephrol Dial Transplant; 2017 Sep; 32(9):1493-1503. PubMed ID: 28339837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular hypertrophy in experimental chronic kidney disease is associated with reduced expression of cardiac Kruppel-like factor 15.
    Patel SK; Velkoska E; Gayed D; Ramchand J; Lesmana J; Burrell LM
    BMC Nephrol; 2018 Jul; 19(1):159. PubMed ID: 29970016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF23 induces left ventricular hypertrophy.
    Faul C; Amaral AP; Oskouei B; Hu MC; Sloan A; Isakova T; Gutiérrez OM; Aguillon-Prada R; Lincoln J; Hare JM; Mundel P; Morales A; Scialla J; Fischer M; Soliman EZ; Chen J; Go AS; Rosas SE; Nessel L; Townsend RR; Feldman HI; St John Sutton M; Ojo A; Gadegbeku C; Di Marco GS; Reuter S; Kentrup D; Tiemann K; Brand M; Hill JA; Moe OW; Kuro-O M; Kusek JW; Keane MG; Wolf M
    J Clin Invest; 2011 Nov; 121(11):4393-408. PubMed ID: 21985788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR signaling-related microRNAs as cardiac hypertrophy modulators in high-volume endurance training.
    Pelozin BRA; Soci UPR; Gomes JLP; Oliveira EM; Fernandes T
    J Appl Physiol (1985); 2022 Jan; 132(1):126-139. PubMed ID: 34792404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
    Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the role of extracellular signal-regulated kinases 1 and 2 in volume overload-induced cardiac remodelling.
    Jochmann S; Elkenani M; Mohamed BA; Buchholz E; Lbik D; Binder L; Lorenz K; Shah AM; Hasenfuß G; Toischer K; Schnelle M
    ESC Heart Fail; 2019 Oct; 6(5):1015-1026. PubMed ID: 31322843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt.
    Kato MF; Shibata R; Obata K; Miyachi M; Yazawa H; Tsuboi K; Yamada T; Nishizawa T; Noda A; Cheng XW; Murate T; Koike Y; Murohara T; Yokota M; Nagata K
    J Hypertens; 2008 Aug; 26(8):1669-76. PubMed ID: 18622247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
    Sanna B; Bueno OF; Dai YS; Wilkins BJ; Molkentin JD
    Mol Cell Biol; 2005 Feb; 25(3):865-78. PubMed ID: 15657416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.